Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

This is a multicenter, single-arm, open, dose-escalation Phase I/II clinical trial, consisting of a dose-escalation phase (accelerated titration phase, 3+3 design) and a dose expansion phase.

Trial Details

NCT ID
NCT06021678
Phase
PHASE1 / PHASE2
Sponsor
Guangzhou Excelmab Inc.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • EX103 injection
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Jinan, Shandong, China|36.66833,116.99722
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • 1\. Provision of signed and dated informed consent form; stated willingness to comply with all study procedures and availability for the duration o…
  • Dose-escalation phase: (1) with CD20-positive non-Hodgkin lymphoma confirmed at the first diagnosis (excluding patients whose CD20 turned negative …
  • Dose-expansion phase:
  • (i) Cohort 1:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →